Sort
48,018 grants matching “immunotherapy”
Novel small molecules for protection against doxorubicin cardiotoxicity in TNBC
$1,062,913Cathy A Swindlehurst · Novomedix, Inc. · R44 · FY2022 · HL
Immunotherapeutic Interventions of AIDS and Cancer
$1,062,472Barbara Felber · Division Of Basic Sciences - Nci · ZIA · FY2017 · CA
Philadelphia Pediatric AIDS Clinical Trials Unit
$1,062,458Children'S Hospital Of Philadelphia · U01 · FY2003 · AI
The TGFÃÂÃÂÃÂÃÂÃÂÃÂÃÂò Signaling Pathway in Development and Cancer
$1,062,000Joan Massague · Sloan-Kettering Inst Can Research · R35 · FY2025 · CA
The TGF Beta Signaling Pathway in Development and Cancer
$1,062,000Joan Massague · Sloan-Kettering Inst Can Research · R35 · FY2020 · CA
THERAPEUTIC ACTIVATION OF IMMUNOGENIC CELL DEATH TO IMPROVE IMMUNOTHERAPY FOR KIDNEY CANCER
$1,062,000Sloan-Kettering Institute For Cancer Research · · FY2022 · Defense Health Agency
Understanding and Mimicking TCR Recognition with Therapeutic Monoclonal Antibodies.
$1,062,000David A Scheinberg · Sloan-Kettering Inst Can Research · R35 · FY2025 · CA
The TGFÃÂÃÂÃÂÃÂÃÂÃÂÃÂò Signaling Pathway in Development and Cancer
$1,062,000Joan Massague · Sloan-Kettering Inst Can Research · R35 · FY2021 · CA
Understanding and Mimicking TCR Recognition with Therapeutic Monoclonal Antibodies.
$1,062,000David A Scheinberg · Sloan-Kettering Inst Can Research · R35 · FY2021 · CA
Biochemical Analysis of Multidrug Resistance-linked Transport Proteins
$1,061,674Suresh Ambudkar · Division Of Basic Sciences - Nci · ZIA · FY2018 · CA
Clinical Evaluation of a Personalized Vaccine Immunotherapy in Combination with Checkpoint Inhibitors for Triple Negative Breast Cancer
$1,061,403Christopher D Pack · Metaclipse Therapeutics Corporation · R44 · FY2021 · CA
Identification of radiosensitizers for prostate cancer
$1,061,377Travis Stracker · Division Of Basic Sciences - Nci · ZIA · FY2023 · CA
TARGETING PCD FOR CANCER THERAPY
$1,061,323University Of Michigan At Ann Arbor · P01 · FY2001 · CA
Targeting intratumor heterogeneity in breast cancer
$1,060,812Kornelia Polyak · Dana-Farber Cancer Inst · R35 · FY2025 · CA
Targeting intratumor heterogeneity in breast cancer
$1,060,812Kornelia Polyak · Dana-Farber Cancer Inst · R35 · FY2022 · CA
Bladder Cancer Program
$1,060,475Andrea Apolo · Division Of Basic Sciences - Nci · ZIA · FY2025 · CA
CAP-IT Center for LNP RNA Immunoprevention
$1,060,438Steven Monroe Lipkin · Weill Medical Coll Of Cornell Univ · U54 · FY2024 · CA
eDyNAmiC - STANFORD
$1,060,406Paul S Mischel · Stanford University · OT2 · FY2022 · CA
Molecular Mechanisms and Treatment Of Autoimmunity In Man And Animal Models
$1,060,049Michael J Lenardo · National Institute Of Allergy And Infectious Diseases · ZIA · FY2020 · AI
Disparities in REsults of Immune Checkpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated with anti-PD-1/anti-PD-L1 in a Community Oncology Setting
$1,059,896Song Yao · Roswell Park Cancer Institute Corp · UG3 · FY2021 · CA
A Phase II Trial of Rituximab In Myasthenia Gravis
$1,059,022Richard Nowak · Yale University · U01 · FY2014 · NS
LJI Epitope Validation Center: Characterization of epitope-specific T cells responding to food, fungal and inner city allergens
$1,058,699Alessandro Sette · La Jolla Institute For Immunology · U19 · FY2020 · AI
Leveraging DNA damage repair pathways as therapeutic targets in womens cancers
$1,058,087Jung-Min Lee · Division Of Basic Sciences - Nci · ZIA · FY2018 · CA
Myelodysplasia
$1,057,808Neal S Young · National Heart, Lung, And Blood Institute · ZIA · FY2012 · HL
Collaborative Protein Technology Resource - Nano-Scale Protein Analysis Section
$1,057,804Jinqiu Chen · Division Of Basic Sciences - Nci · ZIC · FY2020 · CA